RxDoctor Payments Data

Julie Laplante

Family · Concord, NHNPI 1588016430

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 101 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by AbbVie at 30.3% of the total. 2025 is the largest year on record at $1,125, 5.4 times the $206 reported in 2023. Among family clinicians in NH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,269in general payments, 2019–2025

Across 101 payments — averaging $22.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$687
  • Lilly USA, LLC$305
  • Pfizer$246
  • Novo Nordisk$198
  • Merck$162
  • Inspire Medical Systems, Inc.$149
  • plus $522 from 12 others

What the payments were for

  • Food & beverage$2,269100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,269 in reported general payments places this provider in the 90th percentile of 713 family providers in New Hampshire.

See all family providers in New Hampshire

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide14$22,457
SynthroidLevothyroxine Sodium18$1,105
Sertraline Hcl33$379
Levothyroxine Sodium48$358
Albuterol Sulfate HfaAlbuterol Sulfate26$327
Metoprolol Tartrate19$219
Losartan Potassium37$216
Dicyclomine Hcl11$161
Rosuvastatin Calcium11$136
Omeprazole31$131
Atorvastatin Calcium41$115
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav19$104
Simvastatin11$99
Montelukast Sodium15$98
Pantoprazole Sodium12$89

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$305$22,45714 claims
AbbVieSynthroid$687$1,10518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 713 family providers in New Hampshire.

Other family in Concord

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →